Decode will pair its Clinical Genome Miner tool with IBM hardware and software in a joint marketing and sales agreement, the two companies said Jan. 23. Through the agreement, IBM becomes Decode’s preferred IT provider.
For the next three years the companies will co-market and sell the combined system, and will cooperatively provide consulting, implementation, and integration services.
IBM’s contribution will include its eServer pSeries running AIX and its xSeries running Linux. It will also supply its WebSphere infrastructure software and its DB2 database software. The system will make use of DiscoveryLink data integration methods.
Genzyme Molecular Oncology has won a US patent for its LongSAGE technology, the company said Jan. 27. The patent, No. 6,498,013, covers the gene-expression method that is an expansion of the company’s SAGE technique.
Genzyme Molecular President Gail Maderis said the firm is “now performing the majority of our SAGE analysis” using the new patent. “Combining LongSAGE data with our existing SAGE database has accelerated our identification of novel cancer targets,” she added.
LongSAGE uses a tag from each expressed transcript of about 20-22 base pairs in length, according to Genzyme. These tags in turn help identify each transcript.
Luminex and Tm Bioscience have launched Universal Array, a microsphere-based product designed for genotyping and other DNA-based experiments.
The release of the product, based on Luminex's xMAP technology, also triggers a milestone payment from Luminex to Tm Bioscience and the start of a sales-based royalty stream.
“In contrast to planar DNA microarray platforms, the Universal Array provides a reproducible, high-throughput and cost-effective means of nucleic acid testing,” the partners said.